2024
Targeting TREX1 induces innate immune response in drug-resistant Small Cell Lung Cancer
Murayama T, Mahadevan N, Meador C, Ivanova E, Pan Y, Knelson E, Tani T, Nakayama J, Ma X, Thai T, Hung Y, Kim W, Watanabe H, Cai K, Hata A, Paweletz C, Barbie D, Cañadas I. Targeting TREX1 induces innate immune response in drug-resistant Small Cell Lung Cancer. Cancer Research Communications 2024, 4: 2399-2414. PMID: 39177280, PMCID: PMC11391691, DOI: 10.1158/2767-9764.crc-24-0360.Peer-Reviewed Original ResearchConceptsSmall-cell lung cancerPatient-derived xenograftsCells to chemotherapyLung cancerInnate immune responseImmune responseSmall cell lung cancerHuman SCLC tumorsSurvival of resistant cellsResponse to chemotherapyCell lung cancerEfficacy of chemotherapyRepair exonuclease 1Postchemotherapy samplesAntitumor immunitySCLC tumorsCold tumorsAvailable therapiesChromatin immunoprecipitation sequencingTransposase-accessible chromatinInduce immunogenicityChemotherapyResistant cellsTherapeutic strategiesTREX1 expressionTargeting immunogenic cell stress and death for cancer therapy
Galluzzi L, Guilbaud E, Schmidt D, Kroemer G, Marincola F. Targeting immunogenic cell stress and death for cancer therapy. Nature Reviews Drug Discovery 2024, 23: 445-460. PMID: 38622310, PMCID: PMC11153000, DOI: 10.1038/s41573-024-00920-9.Peer-Reviewed Original ResearchImmunogenic cell deathTherapeutic strategiesImmunogenic cell death inducerImmunologically cold tumorsConventional therapeutic strategiesCell deathCancer cell biologyICD inducersCold tumorsAnticancer treatmentCancer therapyCancerCell stressDeathTreatmentCell biologyTranslational effortsImmunotherapyDiscovery platformTumorTherapyInducerLesionsImmunologyTargeting DHX9 triggers tumor-intrinsic interferon response and replication stress in Small Cell Lung Cancer
Murayama T, Nakayama J, Jiang X, Miyata K, Morris A, Cai K, Prasad R, Ma X, Efimov A, Belani N, Gerstein E, Tan Y, Zhou Y, Kim W, Maruyama R, Campbell K, Chen L, Yang Y, Balachandran S, Canadas I. Targeting DHX9 triggers tumor-intrinsic interferon response and replication stress in Small Cell Lung Cancer. Cancer Discovery 2024, 14: 468-491. PMID: 38189443, PMCID: PMC10905673, DOI: 10.1158/2159-8290.cd-23-0486.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerDExD/H-box helicase 9Cell lung cancerCold tumorsLung cancerResponse to immune-checkpoint blockadeInnate immunityEnhance immunotherapy efficacyImmune-checkpoint blockadeImmunogenic tumor microenvironmentImmunologically cold tumorsNucleic acid-sensing pathwaysActivate innate immunityAntitumor immunityImmunotherapy efficacyReplication stressTumor microenvironmentTumor growthViral mimicryTumorImmune responseCancer cellsInterferon responseCytoplasmic dsRNACancer
2022
Intratumoral Therapy to Make a "Cold" Tumor "Hot": The Jury Is Still Out.
Punekar S, Weber J. Intratumoral Therapy to Make a "Cold" Tumor "Hot": The Jury Is Still Out. Clinical Cancer Research 2022, 28: 5007-5009. PMID: 36161479, DOI: 10.1158/1078-0432.ccr-22-2427.Peer-Reviewed Original ResearchMutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma
Shi Y, Xie T, Wang B, Wang R, Cai Y, Yuan B, Gleber-Netto FO, Tian X, Rodriguez-Rosario AE, Osman AA, Wang J, Pickering CR, Ren X, Sikora AG, Myers JN, Rangel R. Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma. Communications Biology 2022, 5: 757. PMID: 35902768, PMCID: PMC9334280, DOI: 10.1038/s42003-022-03675-4.Peer-Reviewed Original ResearchConceptsOral cavity squamous cell carcinomaTumor immune microenvironmentCold tumor immune microenvironmentSquamous cell carcinomaICI therapyOSCC modelCell carcinomaImmune microenvironmentCold tumorsCell death protein 1 (PD-1) inhibitorsCancer cell-intrinsic mechanismsImmune checkpoint inhibitor therapyOral squamous cell carcinomaCheckpoint inhibitor therapyCombination ICI treatmentEffective immunotherapeutic approachesInterferon genes (STING) agonistImmunosuppressive M2 macrophagesProtein 1 inhibitorTobacco-associated cancersICI responsivenessICI treatmentCell-intrinsic mechanismsImmunotherapeutic approachesInhibitor therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply